<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166087</url>
  </required_header>
  <id_info>
    <org_study_id>586/05</org_study_id>
    <nct_id>NCT01166087</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition</brief_title>
  <official_title>A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg Delayed Release Capsules of Eli Lilly and Company, USA in Healthy Adult Human Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to asses the bioequivalence study of Fluoxetine Hydrochloride
      Delayed-Release Capsules, 90 mg and Prozac ® weekly under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open label, two treatment, two period, two sequence, single dose, crossover
      bioequivalence study of Fluoxetine Hydrochloride Delayed-Release capsules 90 mg of Dr.
      Reddy's laboratories limited, Generics, India and Prozac®weekly 90 mg delayed release
      capsules of Eli Lilly and company, USA in healthy adult human subjects under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fluoxetine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prozac ® weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine Hydrochloride</intervention_name>
    <description>Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.</description>
    <arm_group_label>Fluoxetine Hydrochloride</arm_group_label>
    <arm_group_label>Prozac ® weekly</arm_group_label>
    <other_name>Prozac ® weekly 90 mg Delayed Release Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy human subjects between 18-50 years of age (inclusive), weighing as per the
             standard height and weight chart of Life Insurance Corporation of India (11
             Underweight and Overweight Min. &amp; Max. Chart).

          -  Subjects who have no evidence of underlying disease during screening medical history
             and whose physical examination is performed within 21 days prior to commencement of
             the study.

          -  Subjects whose screening laboratory values are within normal limits or considered by
             the physician/Principal Investigator to be of no clinical significance.

          -  Informed consent given in written form according to section 11.3 of the protocol.

          -  Female Subjects

               -  of child bearing potential practicing an acceptable method of birth control for
                  the duration of the study as judged by the investigator(s), such as condoms,
                  foams, jellies,diaphragm, intrauterine device, or abstinence.

               -  postmenopausal for at least I year.

               -  surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject)

        Exclusion Criteria:

          -  Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine,
             immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.

          -  Alcohol dependence, Alcohol abuse, i.e., regular use of more than 2 units of alcohol
             or 10 units per week or a history of alcoholism (one unit of alcohol equals 1/2 1 of
             beer 200 ml wine or 50 ml (of spirits) within last 6 months or recovered alcoholics ,
             or drug abuse within past 1 year.

          -  Moderate to heavy smoking (&gt; 10 cigarettes/day) or consumption of tobacco products.

          -  History of difficulty in swallowing capsules.

          -  Clinically significant illness within 4 weeks before the start of the study.

          -  Asthma, urticaria or other allergic type reactions after taking any medication.

          -  Positive urine drug screening, Human Immunodeficiency Virus, Hepatitis B &amp; C tests.

          -  Any history of hypersensitivity to fluoxetine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. James John, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Labs Private Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Labs Private Limited</name>
      <address>
        <city>Mylapore</city>
        <state>Chennai</state>
        <zip>600 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>July 20, 2010</last_update_submitted>
  <last_update_submitted_qc>July 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. M.S. Mohan / Vice President (Research and Development)</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Fluoxetine Hydrochloride</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

